WCN26-3458 Observation on the Short-Term Efficacy of Telitacicept in the Treatment of Primary IgA Nephropathy

Read full text Summarise with VIRAT
Authors: Xiaoling Gu
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

IgA nephropathy (IgAN) ranks among the most prevalent primary glomerulonephritides globally and significantly elevates the risk of chronic kidney disease and end-stage renal disease. Current supportive care, including angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), often yields suboptimal outcomes, while corticosteroids and immunosuppressants are limited by safety concerns. Telitacicept is a soluble fusion protein composed of the Fc region of human immunoglobulin G1 (IgG1) fused with the extracellular domain of the Transmembrane Activator and CAML Interactor (TACI).

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104321–104321
Publication date
25 March 2026
Language
EN